Rifapentin
Prijeđi na navigaciju
Prijeđi na pretragu
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z,26E)-26[(4-cyclopentylpiperazin-1-yl)amino]methylidene2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25(29)-heptaen-13-yl acetate | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 61379-65-5 | ||
| ATC kod | J04AB05 | ||
| PubChem[1][2] | 5462354 | ||
| DrugBank | APRD01217 | ||
| Hemijski podaci | |||
| Formula | C47H64N4O12 | ||
| Mol. masa | 877.031 g/mol | ||
| |||
| Sinonimi | 3{[(4-cyclopentyl-1-piperazinyl)imino]methyl}rifamycin | ||
| Farmakokinetički podaci | |||
| Bioraspoloživost | povećava se kad je administriran sa hranom | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
Rifapentin, engl. Rifapentine (INN, prodaje kompanija Sanofi-Aventis pod imenom Priftin. Ovaj lek je antibiotik koji se koristi u lečenju tuberkoloze.[3]
Istorija[uredi | uredi kod]
Rifapentin je sintetisan prvi put 1965 godine u kompaniji koja proizvela rifampin (Lepetit Pharmaceuticals). Ovaj lek je FDA odobrila juna juna 1998 godine.
Literatura[uredi | uredi kod]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Rosenthal IM, Zhang M, Williams KN, et al. (December 2007). „Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model”. PLoS Medicine 4 (12): e344. DOI:10.1371/journal.pmed.0040344. PMC 2140085. PMID 18092886.
